Surya Pharmaceutical Ltd
Fortune 500 2012
+ 2 More
+ 2 More
Share
Share
OVERVIEW
FINANCIALS
Featured In Fortune India Ranking
Fortune 500 India
#483(2012)
#364(2011)
#398(2010)
#483(2012)#364(2011)#398(2010)
Ranking Trend Fortune 500 India
Financial Data 2013
Revenue
-28
(INR Cr)
Net Operating Income
90
(INR Cr)
Assets
2,096
(INR Cr)
Profit
-319
(INR Cr)
Net Worth
-78
(INR Cr)
Financial Data
RevenueNet Operating IncomeProfitAssetsNet Worth
| PARAMETERS | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|
| Revenue (INR Cr) | -28 -101.7% | 1653 -15.1% | 1946 42.1% | 1370 68.9% | 811 - |
| Net Operating Income (INR Cr) | 90 -94.83% | 1749 5.52% | 1658 45.12% | 1142 0.00% | 723 48.60% |
| Profit (INR Cr) | -319 - | -304 - | 93 26.6% | 74 31.0% | 56 - |
| Assets (INR Cr) | 2096 -2.5% | 2150 4.7% | 2053 100.2% | 1026 40.3% | 731 - |
| Net Worth (INR Cr) | -78 -134.3% | 228 -56.0% | 518 69.5% | 306 0.0% | 230 28.9% |
| Employee Cost (INR Cr) | 14 -75.8% | 57 19.4% | 48 98.1% | 24 88.2% | 13 - |
| Interest Cost (INR Cr) | 222 | 187 | 109 | 63 | 41 |
| Cash & Bank Balance (INR Cr) | 8 | 16 | 16 | 19 | 8 |
| Total Debt (INR Cr) | 2171 | 1898 | 1476 | 719 | 501 |
Key Financial Ratios
Profit As % Of RevenuesRONW %Interest Cost to EBITDA %ROCE %Debt to Equity Ratio
| PARAMETERS | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|
| Profit As % Of Revenues | - | - | 4.8% | 5.4% | 6.9% |
| Profit As % Of Assets | - | - | 4.5% | 7.2% | 7.7% |
| Profit As % Of Networth | - | - | 18.0% | 24.1% | 24.4% |
| Interest Cost to EBITDA % | - | - | 42.6% | 38.9% | 35.3% |
| Debt to Equity Ratio | - | 8.32 | 2.85 | 2.35 | 2.18 |
| RONW | - | - | 22.4% | 24.3% | 27.5% |
| ROCE | 0.0% | -11.8% | 15.1% | 14.7% | 17.2% |